Evidence map›Paper›PMID 24011826›Full record

Trial reportLeukemia research2013

Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.

Carlos E Vigil, Wei Tan, George Deeb, Sheila N Sait, Annemarie W Block, Petr Starostik, Elizabeth A Griffiths, James E Thompson, Jessica D Greene, Laurie A Ford and 2 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02686593 (Clofarabine, Cytarabine and Mitoxantrone), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02686593 phase2completednot on this mapstarted 2016, after this paper: background citation

Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML

TypeinterventionalSponsorThe University of Hong KongRan2016 to 2018Enrolled50ConditionsAcute Myeloid LeukemiaArmsClofarabine, AraC, mitoxantrone (CLAM)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Carlos E VigilLeukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States.
Wei Tan
George Deeb
Sheila N Sait
Annemarie W Block
Petr Starostik
Elizabeth A Griffiths
James E Thompson
Jessica D Greene
Laurie A Ford
Eunice S Wang
Meir Wetzler

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
NCI NIH HHS CA16056NCI NIH HHS P30 CA016056
6 · The paper itself

Abstract

We designed a phase II study evaluating the upfront combination of clofarabine and daunorubicin in acute myeloid leukemia (AML) patients≥60 years old. The median age of the 21 patients was 69 (range 60-85) years. Fourteen patients (67%) had unfavorable risk features. The principal toxicities were grade ≥3 infections and prolonged myelosuppression. Three (14%) deaths occurred from infectious complications. Six (28.6%) patients achieved complete remission including three (21.4%) of 14 patients with unfavorable AML. The median disease-free survival was 6.8 months and the median overall survival was 11.2 months.

Indexed as

Adenine NucleotidesAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsArabinonucleosidesClofarabineDaunorubicinFemaleFollow-Up StudiesHumansLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplasm StagingPrognosisRemission InductionAdenine NucleotidesArabinonucleosidesClofarabineDaunorubicinAMLClinical trialClofarabineDaunorubicinElderly

Identifiers

PMID24011826
PMCPMC3818466

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.